Cargando…

Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer

Currently there is a limited understanding for the optimal combination of immune checkpoint inhibitor and chemotherapy for patients with metastatic triple-negative breast cancer (mTNBC). Here we evaluate the safety, efficacy, and immunogenicity of a phase I trial for patients with mTNBC treated with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Egelston, Colt A., Guo, Weihua, Yost, Susan E., Ge, Xuan, Lee, Jin Sun, Frankel, Paul H., Cui, Yujie, Ruel, Christopher, Schmolze, Daniel, Murga, Mireya, Tang, Aileen, Martinez, Norma, Karimi, Misagh, Somlo, George, Lee, Peter P., Waisman, James R., Yuan, Yuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10412661/ https://www.ncbi.nlm.nih.gov/pubmed/37294342 http://dx.doi.org/10.1007/s00262-023-03470-y

Ejemplares similares

Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer
por: Egelston, Colt, et al.
Publicado: (2021)

Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast Cancer
por: Ge, Xuan, et al.
Publicado: (2022)

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer
por: Yuan, Yuan, et al.
Publicado: (2023)

Phase 2 prospective open label study of neoadjuvant nab‐paclitaxel, trastuzumab, and pertuzumab in patients with HER2‐positive primary breast cancer
por: Lavasani, Sayeh M., et al.
Publicado: (2022)

Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast Cancer
por: Lee, Jin Sun, et al.
Publicado: (2022)

CF33-hNIS-anti-PD-L1 oncolytic virus followed by trastuzumab-deruxtecan in a patient with metastatic triple negative breast cancer: a case study
por: Yuan, Yuan, et al.
Publicado: (2023)

Tumor-infiltrating exhausted CD8(+) T cells dictate reduced survival in premenopausal estrogen receptor–positive breast cancer
por: Egelston, Colt A., et al.
Publicado: (2022)

Differential gene expression and AKT targeting in triple negative breast cancer
por: Lin, Feng-Mao, et al.
Publicado: (2019)

Immunogenicity of pembrolizumab in patients with advanced tumors
por: van Vugt, Marianne J. H., et al.
Publicado: (2019)

Multi-panel immunofluorescence analysis of tumor infiltrating lymphocytes in triple negative breast cancer: Evolution of tumor immune profiles and patient prognosis
por: He, Ting-Fang, et al.
Publicado: (2020)

Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer
por: Lee, Jin Sun, et al.
Publicado: (2019)

Mature Dendritic Cells May Promote High-Avidity Tuning of Vaccine T Cell Responses
por: Kumbhari, Adarsh, et al.
Publicado: (2020)

Peritumoral Immune-suppressive Mechanisms Impede Intratumoral Lymphocyte Infiltration into Colorectal Cancer Liver versus Lung Metastases
por: Ye, Jian, et al.
Publicado: (2023)

Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
por: Casares, Noelia, et al.
Publicado: (2005)

Doxorubicin-Loaded PLGA Nanoparticles for Cancer Therapy: Molecular Weight Effect of PLGA in Doxorubicin Release for Controlling Immunogenic Cell Death
por: Choi, Yongwhan, et al.
Publicado: (2020)

Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges
por: Lee, Jin Sun, et al.
Publicado: (2020)

Spatial distribution of B cells and lymphocyte clusters as a predictor of triple-negative breast cancer outcome
por: Wortman, Juliana C., et al.
Publicado: (2021)

Mutation and immune profiling of metaplastic breast cancer: Correlation with survival
por: Afkhami, Michelle, et al.
Publicado: (2019)

Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial
por: Pollack, Seth M., et al.
Publicado: (2020)

Dissecting Response to Cancer Immunotherapy by Applying Bayesian Network Analysis to Flow Cytometry Data
por: Rodin, Andrei S., et al.
Publicado: (2021)

Prolonged use of pegylated liposomal doxorubicin in gynecologic malignancies
por: Yost, S., et al.
Publicado: (2019)

Development of proteoglycan-induced arthritis depends on T cell-supported autoantibody production, but does not involve significant influx of T cells into the joints
por: Angyal, Adrienn, et al.
Publicado: (2010)

Hyperglycemia and Glycemic Variability Associated with Glucocorticoids in Women without Pre-Existing Diabetes Undergoing Neoadjuvant or Adjuvant Taxane Chemotherapy for Early-Stage Breast Cancer
por: Mahin, Dana, et al.
Publicado: (2023)

Pathway activity profiling of growth factor receptor network and stemness pathways differentiates metaplastic breast cancer histological subtypes
por: McQuerry, Jasmine A., et al.
Publicado: (2019)

Case Report: Significant Response to the Combination of Lenvatinib and Immune Checkpoint Inhibitor in a Patient With Heavily Pretreated Metastatic Triple Negative Breast Cancer
por: Lee, Jin Sun, et al.
Publicado: (2021)

Pembrolizumab
por: Khoja, Leila, et al.
Publicado: (2015)

Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple negative breast and ovarian carcinomas
por: Menghi, Francesca, et al.
Publicado: (2022)

Synergic fabrication of pembrolizumab loaded doxorubicin incorporating microbubbles delivery for ultrasound contrast agents mediated anti-proliferation and apoptosis
por: Liu, Huilin, et al.
Publicado: (2021)

Doxorubicin‐loaded nanoparticle coated with endothelial cells‐derived exosomes for immunogenic chemotherapy of glioblastoma
por: Zhang, Chao, et al.
Publicado: (2020)

Association of Pre‐Chemotherapy Peripheral Blood Pro‐Inflammatory and Coagulation Factors with Physical Function in Women with Breast Cancer
por: Yuan, Yuan, et al.
Publicado: (2017)

Pembrolizumab for all
por: Kim, Myung S., et al.
Publicado: (2022)

Labor Complicated with Monstrosity
por: Egelston, J. Q.
Publicado: (1854)

Doxorubicin and resveratrol co-delivery nanoparticle to overcome doxorubicin resistance
por: Zhao, Yuan, et al.
Publicado: (2016)

Complete Response of Triple-Negative Metaplastic Carcinoma of the Breast Using Pembrolizumab
por: Ladwa, Amrita, et al.
Publicado: (2023)

Oligometastatic Breast Cancer Patients Treated with High-Dose Chemotherapy and Targeted Radiation: Long-Term Follow-Up of a Phase II Trial
por: Ladbury, Colton, et al.
Publicado: (2022)

iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells
por: De Boo, Sara, et al.
Publicado: (2009)

Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18
por: Alagkiozidis, Ioannis, et al.
Publicado: (2009)

Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial
por: Takahashi, Masato, et al.
Publicado: (2023)

Readministration of Pembrolizumab after Treatment of Tuberculosis Activated by Initial Pembrolizumab Therapy
por: Murakami, Shuji, et al.
Publicado: (2020)

A Phase 2 Trial Combining Pembrolizumab and Palliative Radiation Therapy in Gastroesophageal Cancer to Augment Abscopal Immune Responses
por: Chao, Joseph, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ai5vb2o4ksl1gvkkbvf593qgjv